{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:36:59Z","timestamp":1793399819386,"version":"4.5.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Patients with diabetes mellitus have an increased risk of fractures; however, the underlying mechanism is largely unknown. We aimed to investigate whether the risk of major osteoporotic fractures in diabetes patients differs between subjects initiated with alendronate and denosumab, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Research Design<\/jats:title>\n                    <jats:p>We conducted a retrospective nationwide cohort study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. We identified all subjects with a diabetes diagnosis between 2000 and 2018 and collected data on the first new prescription of anti-osteoporotic treatment between 2011 and 2018. Exposure was defined as either alendronate or denosumab treatment initiated after diabetes diagnosis. Outcome information was collected by identification of all major osteoporotic fracture (MOF) diagnoses, i.e., hip, spine, forearm, and humerus, from exposure until 2018 or censoring by emigration or death. The risk of fracture was calculated as hazard ratios (HR) using multiply adjusted Cox proportional models with death as a competing risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 8,745 subjects initiated with either alendronate (n = 8,255) or denosumab (n = 490). The cohort consisted of subjects with a mean age of 73.62 (SD \u00b1 9.27) years, primarily females (69%) and suffering mainly from type 2 diabetes (98.22%) with a median diabetes duration at baseline of 5.45 years (IQR 2.41\u20139.19). Those in the denosumab group were older (mean 75.60 [SD \u00b1 9.72] versus 73.51 [SD \u00b1 9.23] years), had a higher proportion of women (81% versus 68%, RR 1.18 [95% CI 1.13\u20131.24], and were more comorbid (mean CCI 2.68 [95% CI 2.47\u20132.88] versus 1.98 [95% CI 1.93\u20132.02]) compared to alendronate initiators. In addition, denosumab users had a higher prevalence of previous fractures (64% versus 46%, RR 1.38 [95% CI 1.28\u20131.48]). The\u00a0adjusted HR for any MOF after treatment initiation with denosumab was 0.89 (95% CI 0.78\u20131.02) compared to initiation with alendronate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The risk of incident MOF among subjects with diabetes was similar between those initially treated with alendronate and denosumab. These findings indicate that the two treatment strategies are equally effective in preventing osteoporotic fractures in subjects with diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2021.826997","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:06:58Z","timestamp":1643155618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Rikke","family":"Viggers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheer","family":"Al-Mashhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Starup-Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90218-e","article-title":"Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis","volume":"94","year":"1993","journal-title":"Am J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.192914","article-title":"Bone Turnover Markers: Emerging Tool in the Management of Osteoporosis","volume":"20","author":"Shetty","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2676-7","article-title":"Biochemical Markers of Bone Turnover in Diabetes Patients -\u00a0A Meta-Analysis, and a Methodological Study on the Effects of Glucose on Bone Markers","volume":"25","author":"Starup-Linde","year":"2014","journal-title":"Osteoporosis Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in Bone Mineral Density and Fracture Risk in Patients With Type 1 and Type 2 Diabetes -\u00a0A Meta-Analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporosis Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051248","article-title":"Diabetes Mellitus and the Incidence of Hip Fracture: Results From the Nord-Trondelag Health Survey","volume":"42","author":"Fors\u00e9n","year":"1999","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/J.BONE.2020.115457","article-title":"The Risk of Hip and non-Vertebral Fractures in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis Update","volume":"137","author":"Vilaca","year":"2020","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/DC19-0925","article-title":"Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone","volume":"43","author":"Koromani","year":"2020","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6969040","DOI":"10.1155\/2016\/6969040","article-title":"Sweet Bones: The Pathogenesis of Bone Alteration in Diabetes","volume":"2016","author":"Al-Hariri","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised Trial of Effect of Alendronate on Risk of Fracture in Women With Existing Vertebral Fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"B10","unstructured":"Prolia | European Medicines Agency"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J Clin Densitometry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658","article-title":"Osteoclast Differentiation and Activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women With Osteoporosis: A Meta-Analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the Comparison of Effectiveness Between Denosumab and Bisphosphonates in Post-Menopausal Osteoporosis","volume":"2","author":"Benjamin","year":"2016","journal-title":"Osteoporosis Sarcopenia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0809010","article-title":"Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Mineral Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/JBMR.090716","article-title":"Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Mineral Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the Phase 3 Randomised FREEDOM Trial and Open-Label Extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-Analysis of How Well Measures of Bone Mineral Density Predict Occurrence of Osteoporotic Fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture Incidence and Association With Bone Mineral Density in Elderly Men and Women: The Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.7.1547","article-title":"Effect of Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Type 2 Diabetic Women: The Fracture Intervention Trial","volume":"27","author":"Keegan","year":"2004","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115268","article-title":"Denosumab in Postmenopausal Women With Osteoporosis and Diabetes: Subgroup Analysis of FREEDOM and FREEDOM Extension","volume":"134","author":"Ferrari","year":"2020","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0652","article-title":"Diabetes Mellitus, a State of Low Bone Turnover-a Systematic Review and Meta-Analysis","volume":"176","author":"Hygum","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0652","article-title":"MECHANISMS IN ENDOCRINOLOGY: Diabetes Mellitus, a State of Low Bone Turnover -\u00a0a Systematic Review and Meta-Analysis","volume":"176","author":"Hygum","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2015.02.019","article-title":"Biochemical Bone Turnover Markers in Diabetes Mellitus -\u00a0A Systematic Review","volume":"82","author":"Starup-Linde","year":"2016","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a Tool in Epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/clep.s37587","article-title":"Existing Data Sources for Clinical Epidemiology: The Danish National Database of Reimbursed Prescriptions","volume":"4","author":"Johannesdottir","year":"2012","journal-title":"Clin Epidemiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: A Review of Content, Data Quality, and Research Potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(00)00158-4","article-title":"Hormonal Replacement Therapy Reduces Forearm Fracture Incidence in Recent Postmenopausal Women - Results of the Danish Osteoporosis Prevention Study","volume":"36","author":"Mosekilde","year":"2000","journal-title":"Maturitas"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01447-x","article-title":"Association of Severe Hypoglycemia With Mortality for People With Diabetes Mellitus During a 20-Year Follow-Up in Denmark: A Cohort Study","volume":"57","author":"Jensen","year":"2020","journal-title":"Acta Diabetol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2535","article-title":"Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users","volume":"43","author":"Jensen","year":"2020","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3225","article-title":"Risk of Major Cardiovascular Events, Severe Hypoglycaemia, and All-Cause Mortality for Users of Insulin Degludec Versus Insulin Glargine U100\u2014A Danish Cohort Study","volume":"36","author":"Jensen","year":"2020","journal-title":"Diabetes\/Metabolism Res Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/DC21-0333","article-title":"Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study","volume":"44","author":"Viggers","year":"2021","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.771426","article-title":"Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study","author":"Viggers","year":"2021","journal-title":"Front Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S163037","article-title":"Concordance Assessment of Self-Reported Medication Use in the Netherlands Three-Generation Lifelines Cohort Study With the Pharmacy Database Iadb.Nl: The Pharmlines Initiative","volume":"10","author":"Sediq","year":"2018","journal-title":"Clin Epidemiol"},{"key":"B39","first-page":"3","article-title":"Comparability of Self-Reported Medication Use and Pharmacy Claims Data","volume":"24","author":"Allin","year":"2013","journal-title":"Health Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1763","article-title":"Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany","volume":"41","author":"K\u00e4hm","year":"2018","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.diabres.2016.12.004","article-title":"Second Line Initiation of Insulin Compared With DPP-4 Inhibitors After Metformin Monotherapy is Associated With Increased Risk of All-Cause Mortality, Cardiovascular Events, and Severe Hypoglycemia","volume":"123","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14070","article-title":"Days Absent From Work as a Result of Complications Associated With Type 2 Diabetes: Evidence From 20 Years of Linked National Registry Data in Sweden","volume":"22","author":"Persson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B43","article-title":"Use and Validation of Public Data Files for Identification of the Diabetic Population in a Danish County","volume":"48","author":"Kristensen","year":"2001","journal-title":"Dan Med Bull"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3233\/jrs-1997-10309","article-title":"The Pharmacoepidemiologic Prescription Database of North Jutland -\u00a0A Valid Tool in Pharmacoepidemiological Research","volume":"10","author":"Nielsen","year":"1997","journal-title":"Int J Risk Saf Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0083436","article-title":"FRAX\u00ae: Prediction of Major Osteoporotic Fractures in Women From the General Population: The OPUS Study","volume":"8","author":"Briot","year":"2013","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4603-9","article-title":"Social Inequality and Fractures\u2014Secular Trends in the Danish Population: A Case-Control Study","volume":"29","author":"Hansen","year":"2018","journal-title":"Osteoporosis Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The Predictive Value of ICD-10 Diagnostic Coding Used to Assess Charlson Comorbidity Index Conditions in the Population-Based Danish National Registry of Patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Method"},{"key":"B49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/J.BONE.2010.11.020","article-title":"Denosumab and Bisphosphonates: Different Mechanisms of Action and Effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641","article-title":"Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Mineral Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2416","article-title":"Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation","volume":"2","author":"Pedersen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2018.05.020","article-title":"Effect of a Bisphosphonate and Selective Estrogen Receptor Modulator on Bone Remodeling in Streptozotocin-Induced Diabetes and Ovariectomized Rat Model","volume":"18","author":"Lee","year":"2018","journal-title":"Spine J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1055\/s-0042-105282","article-title":"Zoledronic Acid Improves Bone Quality in the Streptozotocin-Induced Diabetes Rat Through Affecting the Expression of the Osteoblast-Regulating Transcription Factors","volume":"127","author":"Cui","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9450-4","article-title":"Are Antiresorptive Drugs Effective Against Fractures in Patients With Diabetes","volume":"88","author":"Vestergaard","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1548-x","article-title":"Efficacy of Anti-Osteoporotic Medications in Patients With Type 1 and 2 Diabetes Mellitus: A Systematic Review","volume":"60","author":"Anagnostis","year":"2018","journal-title":"Endocrine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1865","article-title":"Effects of Antiresorptive Therapies on Glucose Metabolism: Results From the FIT, HORIZON-PFT, and FREEDOM Trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Bone Mineral Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/JDI.13458","article-title":"Beneficial Effects of Switching to Denosumab From Bisphosphonates or Selective Estrogen Receptor Modulators in Postmenopausal Women With Type 2 Diabetes and Osteopenia\/Osteoporosis","volume":"12","author":"Miyoshi","year":"2021","journal-title":"J Diabetes Invest"},{"key":"B59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/J.BONE.2013.10.006","article-title":"Denosumab Compared With Risedronate in Postmenopausal Women Suboptimally Adherent to Alendronate Therapy: Efficacy and Safety Results From a Randomized Open-Label Study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.296.24.2927","article-title":"Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-019-00513-1","article-title":"Falls and Fractures in Diabetes\u2014More Than Bone Fragility","volume":"17","author":"Rasmussen","year":"2019","journal-title":"Curr Osteoporosis Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125915","article-title":"RANKL Inhibition Improves Muscle Strength and Insulin Sensitivity and Restores Bone Mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12944","article-title":"Alendronate Improves Fasting Plasma Glucose and Insulin Sensitivity, and Decreases Insulin Resistance in Prediabetic Osteopenic Postmenopausal Women: A Randomized Triple-Blind Clinical Trial","volume":"10","author":"Karimi Fard","year":"2019","journal-title":"J Diabetes Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-011-9515-z","article-title":"Risk of Newly Diagnosed Type 2 Diabetes is Reduced in Users of Alendronate","volume":"89","author":"Vestergaard","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4943(01)00202-3","article-title":"Alendronate Reduces the Daily Consumption of Insulin (DCI) in Patients With Senile Type I Diabetes and Osteoporosis","volume":"34","author":"Maugeri","year":"2002","journal-title":"Arch Gerontol Geriatr"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123279","article-title":"The Use of Alendronate is Associated With a Decreased Incidence of Type 2 Diabetes Mellitus -\u00a0A Population-Based Cohort Study in Taiwan","volume":"10","author":"Chan","year":"2015","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3481","article-title":"Bisphosphonates and Glucose Homeostasis: A Population-Based, Retrospective Cohort Study","volume":"100","author":"Toulis","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4650-2","article-title":"Diagnosis and Management of Bone Fragility in Diabetes: An Emerging Challenge","volume":"29","author":"Ferrari","year":"2018","journal-title":"Osteoporosis Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5462.2398","article-title":"When an Entire Country is a Cohort","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"key":"B70","article-title":"The National Patient Registry. Evaluation of Data Quality","volume-title":"Ugeskr Laeger","author":"Mosbech","year":"1995"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse Effects of Bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1188","article-title":"High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study","volume":"36","author":"Oei","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.826997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:07:04Z","timestamp":1643155624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.826997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":72,"alternative-id":["10.3389\/fendo.2021.826997"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.826997","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"article-number":"826997"}}